The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type. More: FDA approves Ono's rare tumor drug from .4B Deciphera buyout Source: fierce
read moreThe company’s Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo, respectively. More: With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring Source: fierce
read moreIn 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, which included a major $238 million charge tied to the cancellation of a contract manufacturing agreement toward the end of the year. More: Moderna shoulders 8M contract
read moreA group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency catering to pharmaceutical, biotech, medtech and health tech clients. More: Inizio Evoke alums flex healthcare marketing prowess with launch
read moreAstellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi “expansion phase” on the horizon.
read moreBristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected
read more© 1994 - 2025 B.M. Pharmaceuticals